TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma
Zachary A. Glaser(University of Alabama at Birmingham), Peter E. Clark(Levine Cancer Institute), Lan L. Gellert(Vanderbilt University Medical Center), Michael S. Cookson(University of Oklahoma Health Sciences Center), S. Duke Herrell(Vanderbilt University Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), Sam S. Chang(Vanderbilt University), Shunhua Guo(Vanderbilt University Medical Center), Harold D. Love(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center)
Cited by 33
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845